On January 7, 2020, Deep Genomics closed its US$40 million Series B financing round led by Future Ventures. The funding will be used to develop treatments for rare genetic diseases as well as fund in the expansion of Deep Genomics’ AI based drug discovery platform. The financing round will also allow Deep Genomics to bring its program focused on Wilson disease into the clinic and enable strategic partnerships with larger health-focused firms.
Deep Genomics is a Toronto based, growth stage AI therapeutics firm with a focus on healthcare technology. The company is specialized in enabling a new approach to drug development through deep learning based technology in order to help geneticists, chemists and molecular biologists create therapies.
Future Ventures is a Venture Capital firm focused on early-stage investments in disruptive technology such as commercial space exploration, deep learning, quantum computing, robotics, AI, blockchain, sustainable transportation, synthetic biology and clean meat.
Osler, Hoskin & Harcourt LLP advised Deep Genomics with a team consisting of Chad Bayne, Justin Dharamdial and Theresa Donkor (Emerging and High Growth Companies).
Key Contact
Partner, Emerging and High Growth Companies, Toronto
Team
Partner, Emerging and High Growth Companies, Toronto
